

1 Original Research Article

2 **RNA-extraction-free diagnostic method to detect SARS-CoV-2: an assessment**  
3 **from two States, India**

4 Madhumathi Jayaprakasam<sup>1</sup>, Sumit Aggarwal<sup>1</sup>, Arati Mane<sup>2</sup>, Vandana Saxena<sup>2</sup>, Amrita Rao<sup>2</sup>,  
5 Bhaswati Bandopadhyay<sup>3</sup>, Banya Chakraborty<sup>3</sup>, Subhasish Kamal Guha<sup>3</sup>, Mekhala Taraphdar<sup>3</sup>,  
6 Alisha Acharya<sup>3</sup>, Bishal Gupta<sup>3</sup>, Sonia Deb<sup>3</sup>, Aparna Chowdhury<sup>3</sup>, Kh Jitenkumar Singh<sup>4</sup>,  
7 Prashant Tapase<sup>4</sup>, Ravindra M Pandey<sup>5</sup>, Balram Bhargava<sup>1</sup>, Samiran Panda<sup>1\*</sup>

8 <sup>1</sup> Division of Epidemiology and Communicable Diseases, Indian Council of Medical research  
9 (ICMR), Ansari Nagar, New Delhi, India

10 <sup>2</sup> Department of Microbiology, ICMR- National AIDS Research Institute (NARI), Pune, India

11 <sup>3</sup> Department of Microbiology, School of Tropical Medicine, Kolkata, India

12 <sup>4</sup> ICMR-National Institute of Medical Statistics (NIMS), Ansari Nagar, India

13 <sup>5</sup> Department of Biostatistics, All India Institute of Medical Sciences (AIIMS), New Delhi, India

14  
15

\*Corresponding author

16 Dr Samiran Panda

17 Head, Division of Epidemiology and Communicable Diseases

18 Indian Council of Medical research (ICMR)

19 Ansari Nagar, New Delhi-110029

20 Director, ICMR-National AIDS Research Institute

21 E mail: [pandasamiran@gmail.com](mailto:pandasamiran@gmail.com)

22 Phone: (+91) 9830908475

23 Fax no: 011-26588896

24  
25

26 **Word Count** (excluding summary, declarations, references, figures, tables, figure legends):

27 3194

## 28 **RNA-extraction-free diagnostic method to detect SARS-CoV-2: an assessment** 29 **from two States, India**

### 30 **Summary**

31 With increasing demand for large numbers of testing during COVID-19 pandemic, came  
32 alternative protocols with shortened turn-around time. We evaluated the performance of such an  
33 approach wherein 1138 consecutive clinic attendees were enrolled; 584 and 554 respectively  
34 from two independent study sites in the cities of Pune and Kolkata. Paired nasopharyngeal and  
35 oropharyngeal swabs were tested by using both reference and index methods in blinded fashion.  
36 Prior to conducting RT-PCR, swabs collected in viral transport medium (VTM) were processed  
37 for RNA extraction (reference method) and swabs collected in dry tube without VTM were  
38 incubated in Tris-EDTA-Proteinase K buffer for 30 minutes and heat inactivated at 98°C for 6  
39 minutes (index method). Overall sensitivity and specificity of the index method were 78.9%  
40 (95% CI 71% to 86%) and 99 % (95% CI 98% to 99.6%) respectively. Agreement between the  
41 index and reference method was 96.8 % ( $k = 0.83$ ,  $SE=0.030$ ). The reference method exhibited  
42 enhanced detection of viral genes (E, N and RdRP) with lower Ct values compared to the index  
43 method. The index method can be used for detecting SARS-CoV-2 infection with appropriately  
44 chosen primer-probe set and heat treatment approach in pressing time; low sensitivity constrains  
45 its potential wider use.

### 46 **Key words**

47 SARS CoV-2, RNA-extraction free method, Diagnostic test, Heat-inactivation, Dry swab,  
48 Performance-evaluation

## Introduction

49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71

The COVID-19 pandemic swept through the world with unprecedented speed and impact on lives and livelihoods [1]. Within four months of its onset, more than 118,000 cases and 4,291 deaths were reported from 114 countries. All of these happened following an outbreak of ‘unusual cases of pneumonia’ notified for the first time from the Wuhan city of Hubei province, China in December 2019 [2]. Such a rapid spread of the causative virus SARS-CoV-2 reminded humankind of the influenza pandemic causing havoc about 100 year ago [3,4]. Developing simple and reliable diagnostic tests appeared paramount in this context as care service related needs escalated and demand for tools to conduct quick screening and survey also increased [5].

As with many other infectious diseases, SARS-CoV-2 infection is detected reliably by the real-time polymerase chain reaction (RT-PCR) as it is a highly sensitive and specific tool [6]. While the Center for Disease Control (CDC), USA recommended the gene targets for two nucleocapsid proteins (N1 and N2) of SARS-CoV-2 for diagnostic assays [7], the World Health Organization (WHO) proposed using envelope (E) gene target for first line screening and RNA dependent RNA Polymerase (RdRP) for confirmation [8,9]. Notably, assays using E and N2 gene primers were found to be more sensitive [10]. The combination of two gene targets is recommended to enhance accuracy of diagnosis in the context of possible viral genetic variability; one from the conserved region of the virus and another from SARS CoV-2 specific region of the genome [8].

Several alternative protocols described ways to simplify RT-PCR test by excluding the RNA extraction step [11-14]. These modifications attempted to reduce the turn-around time for

72 quickly obtaining test results and also to address the issue of shortage of RNA extraction kits  
73 when the demand runs high. Heating of naso-pharyngeal swab specimens in transport medium  
74 and skipping RNA extraction step before proceeding to conduct RT-PCR has been reported to be  
75 fast and reliable [12]. Direct heating of viral extracts from swab specimens for 5 minutes at 98  
76 °C resulted in 97% sensitivity and 100% specificity when examined against purified RNA as  
77 gold standard [15]. Direct RT-PCR assay with heat-inactivated or lysed samples using generic  
78 buffers like Tris or Tris-EDTA (TE) served as an effective alternative method [16]. A similar  
79 approach to RT-PCR, using heat inactivated TE buffer extract of nasopharyngeal swabs  
80 transported in dry tube from sample collection site to the laboratory, has been described from  
81 India as well [17]. However, utility of this method and modified version of it as suggested by the  
82 Centre for Cellular and Molecular Biology, Hyderabad, India in real world program setting was  
83 not examined. This modification was in line with the work of Chu et al [13] for SARS CoV-2  
84 and de Paula et al., [18] for Hepatitis A virus where proteinase K was used along with TE buffer.  
85 We assessed the performance of modified version of the test approach of Kiran et al., in program  
86 setting for diagnosis of COVID-19, using E, RdRP and N primer-probe based assay.

## 87 **Methods**

88 The current investigation took place during 10<sup>th</sup> November through 11<sup>th</sup> December 2020. The  
89 proposal for evaluation was developed in early October 2020 and approval was obtained from  
90 the Central Ethics Committee for Human Research (CECHR) of Indian Council of Medical  
91 Research (ICMR) on 30<sup>th</sup> October 2020. Written informed consent was obtained from  
92 individuals consenting to participate in this study.  
93  
94

### *Study settings and participants*

95 The present investigation was conducted at two sites in India namely, the ICMR-National AIDS  
96 Research Institute (ICMR-NARI), Pune in the western state of Maharashtra and the School of  
97 Tropical Medicine (STM), Kolkata in the eastern state of West Bengal. Necessary approvals  
98 were obtained from the Ethics Committees of these two respective institutes as well. Consecutive  
99 clinic attendees ( $\geq 18$  year of age) at the designated study sites, who came for SARS-CoV-2  
100 testing, were invited to participate in this investigation.  
101

### *Implementation*

102  
103 Each consenting clinic attendee was registered on a web-based portal maintained by ICMR with  
104 a specimen referral form (SRF) number created at the collection site, which was used for labeling  
105 the viral transport medium (VTM) containing tube. In order to ensure blinding, a different set of  
106 unique codes were randomly generated from the ICMR-headquarter, New Delhi for each study  
107 site using Excel based tool for labelling the corresponding swabs collected and placed in dry  
108 tubes. The link page, containing ICMR SRF number and the paired unique code for swabs in dry  
109 tubes for each enrolled participant, was available only with the designated staff at the respective  
110 study sites. Blinding was ensured through barring of the laboratory staff involved in test  
111 procedures and generation of test results to the link page.  
112

### *Sample collection and processing*

113  
114 ‘Specimen Collection, Packaging and Transport Guidelines for 2019 Novel Coronavirus (2019-  
115 nCoV)’, was adhered to during study implementation [19]. Two naso-pharyngeal swabs and two  
116 oro-pharyngeal swabs were collected from each of the enrolled participants in single sitting. The  
117

118 swabs (one naso-pharyngeal and one oro-pharyngeal) saved in labelled VTM tubes and those  
119 kept in labelled dry tubes, were transported to the participating laboratories and processed on the  
120 same day of sample collection.

121  
122 *Reference test and Index test*

- 123 *i. RT-PCR test with swab specimens transported in VTM tube (reference method):* The  
124 reference method used one nasopharyngeal and one oropharyngeal swab (HiMedia™  
125 Laboratories Pvt Ltd, Mumbai, India) collected from each participant and saved in the tube  
126 containing 3 ml VTM (HiMedia™ Laboratories Pvt Ltd, Mumbai, India). About 200 µl of  
127 the VTM extract was used for RNA extraction followed by RT-PCR assay [9].
- 128 *ii. Dry swab-based RT-PCR (index method):* One nasopharyngeal swab and one  
129 oropharyngeal swab collected from each participant were transported to the laboratories in  
130 10 ml sample collection tubes (HiMedia™ Laboratories Pvt Ltd, Mumbai, India) without  
131 adding VTM to them. At the laboratories 400 µl of Tris-EDTA-Proteinase K (TE-P) buffer  
132 [10mM Tris (pH 7.4), 0.1mM EDTA, and 2 mg/ml Proteinase K] (Bio Ultra, for molecular  
133 biology, Sigma-Aldrich, Bangalore, India) was added to swab specimens transported in dry  
134 tube and incubated for 30 minutes at room temperature. About 50 µl of the TE-P extract  
135 was aliquoted into PCR tube and was heat inactivated at 98°C for 6 minutes using thermal  
136 cyclor (ICMR-NARI site) or heat block (STM site). The heat inactivated extract was then  
137 used as template for RT-PCR reaction (Figure 1).

138  
139  
140

### *Nucleic Acid Amplification Assay*

141 RNA extraction from clinical specimens transported in VTM tubes was carried out as per  
142 instructions accompanying the commercial RNA extraction kit (QIAmp viral RNA Mini Kit,  
143 QIAGEN, New Delhi, India). The RT-PCR reaction was carried out using ‘CoviDx mPlex-4R  
144 SARS-CoV-2’ (NeoDx Biotech Labs Private Limited, DSS Imagetech, New Delhi, India) as per  
145 manufacturer’s instructions with primer-probe sets (Table 1) for detection of the SARS-CoV-2  
146 specific genes E, N and RdRP. Human RNase P was used as internal control in this single tube  
147 assay. Briefly, a 25 µl reaction was set up containing 8 µl template (purified RNA from VTM  
148 sample for reference method and heat inactivated dry swab lysate for index method), 12.5 µl of  
149 2X master mix, 1.25 µl 20X primer and probe mix and 3.25 µl nuclease free water. In each assay  
150 a positive control and no template control (NTC) were included. The RT-PCR assays were  
151 conducted on ‘CFX96-IVD Real-time PCR system’ (Bio-Rad Laboratories India Pvt. Ltd.,  
152 Gurugram, Haryana, India) using the following cycling conditions; 50 °C for 15 minutes for  
153 reverse transcription, 95 °C for 2 minutes, and 45 cycles of 95 °C for 15 s and 58 °C for 30 s.  
154

### *Sample size estimation and data analysis*

156 An earlier evaluation of the RNA-extraction-free dry swab-based RT-PCR method [17] in clinic  
157 setting was conducted by us and estimated to have 56% sensitivity and 95% specificity [20]. The  
158 modified index method (described above) was expected to have improved sensitivity and thus we  
159 conservatively assumed it to be 75% with minimum acceptance lower confidence limit of 60%  
160 based on which the calculated number of cases required was 107 [21]. With the recorded  
161 prevalence of 20 % SARS-CoV-2 infection among clinic attendees in Pune and Kolkata during  
162

163 the current study, the number of SARS-CoV-2 negative individuals to be included was calculated  
164 as  $428 \{107 \times (1-0.2/0.2)\} = 428$ ; the total estimated sample size being 535.

165 A cycle threshold (Ct) value of 40 or less was considered as positive. The binary outcome  
166 (yes/no), in the form of presence or absence of SARS-CoV-2 infection generated by the index  
167 method was assessed against the results obtained following RT-PCR tests on swab specimens  
168 transported in VTM. The sensitivity, specificity, concordance, discordance, positive predictive  
169 value, negative predictive value and agreement between the tests and their 95% confidence  
170 interval (CI) were computed using Stata version 13.1 (StataCorp LP, College Station, TX, USA).  
171 Graphpad Prism (version 5) and R-CRAN (version 4.0.3) with ggplot2 library was used for  
172 graphical representations.  
173

## 174 **Results**

### 175 *Participants*

176 Consecutive clinic attendees at the two study sites were enrolled. While 15 of the 600 (2.5%)  
177 attendees at ICMR-NARI, Pune site refused to provide consent, 96 of the 650 attendees at STM,  
178 Kolkata (14.8%) did so. Information obtained from 584 participants by ICMR-NARI (one  
179 specimen could not be analyzed due to inadequate volume) and 554 participants by STM,  
180 Kolkata were included in the analyses. Each site thus fulfilled sample size requirement on its  
181 own and allowed examination of performance of the index test in two different real world  
182 settings independent of each other and thus fulfilling the criteria of conducting evaluation in  
183 different settings.  
184



185 The majority of the participants were male (767/1138; 67%); age ranging from 18 to 85 year  
186 (Table 2). Nearly 30% of the participants were symptomatic (342/1138); most common ones  
187 being fever (52%), cough (35%), bodyache (12%), sore throat (7%), breathlessness (3.5%) and  
188 anosmia (3.5%).

189  
190 *Comparison of Ct values - reference vs index method*

191 Heat-maps of Ct values for E, RdRP and N genes detected by reference and index methods were  
192 plotted. Samples, which were detected having at least one of these genes by VTM-based method,  
193 were used for comparisons and were examined to explore how did the index method perform  
194 against them. The N gene primer-probe set showed superior performance compared to the other  
195 two genes by both reference and index methods. Figure 2 presents comparative data visualization  
196 with juxtaposition pertaining to the three aforementioned genes along with the internal control  
197 (human Rnase P). The reference method could detect either one of the three genes (E, RdRP or N  
198 gene) in 54 samples at ICMR-NARI and 71 samples at STM. However, the index method could  
199 detect either one of the three genes in 45 out of the aforementioned 54 samples at ICMR-NARI  
200 and 55 of the 71 samples at STM (Figure 2a & 2b). The index method could not detect any of the  
201 three target genes in 17 % (9/54) of the clinical specimens at ICMR-NARI and the proportion of  
202 such missed events had risen to 23 % (16/71) at STM. Parity between the reference and  
203 extraction free methods in terms of detecting positive specimens was better at ICMR-NARI  
204 (45/54; 83.3 %) (Fig 2a) compared to the results obtained at STM (55/71; 77.5 %) (Fig 2b). This  
205 difference could be explained by the difference in heat treatment methods used by the respective  
206 centres. While the STM site used heat block for maintaining 98°C at 6 minutes, the ICMR-NARI  
207 site had used thermal cycler.

### *Distribution of Ct values*

208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230

We compared matched Ct values generated by both reference as well as index method. Samples which were tested positive by reference method for each gene were used for the analysis of Ct values. Reference method-based RT-PCR results had 1-10 Ct values lesser than those generated by index method for E, RdRP and N genes in more than two-third of the samples (Figure 3). The mean Ct values ( $\pm$  SD) for target genes detected by reference method were as follows; E= 23.69  $\pm$  4.03, RdRP = 25.59  $\pm$  4.06 and N = 25.76  $\pm$  5.33. These values were significantly lower ( $p < 0.0001$ , Wilcoxon signed rank test), compared to the values generated by the dry swab method (E = 24.42  $\pm$  4.01, RdRP = 26.80  $\pm$  3.32 and N = 26.61  $\pm$  4.87).

### *Performance of index method*

While 11% (128/1138) of the total clinic attendees tested positive for SARS-CoV-2 infection by the reference method, the index method involving transportation of swabs in dry tube environment detected 78% (101/128) of them thus reducing the overall detection to 8.8% (101/1138). Of the 584 samples tested at ICMR-NARI site, overall 9.6% samples (56/584) tested positive by reference method and 9.4% (55/584) were positive by index method. Of the 554 samples tested at STM, Kolkata, 72 (13%) were detected as positive by reference method and 55 (10%) by index method (Figure 4). The overall sensitivity of the index method was 78.9 % (95% CI 71% to 86%) and specificity was 99 % (95% CI 98% to 99.6%). The observed overall agreement between the index and reference method was 96.8 % and the discordance was 3.16 %; kappa value ( $k$ ) was 0.83 (95% CI 0.77 to 0.89, SE=0.030). Site disaggregated data are presented in Table 3.

## Discussion

231  
232 Conducting research during outbreak situation faces many challenges. Lengthy start-up period  
233 before one could carry out observational research in pandemic situation has been cited as one of  
234 these challenges [22], and the other challenges are reactive approaches, socio-political pressures  
235 to approve repurposed or promising drugs [23] or diagnostic kits and urgency of the researchers  
236 to inform public health decisions. Besides prompt implementation against such background, the  
237 strength of the current investigation rests with its methodology. Firstly, a study population akin  
238 to the individuals, on which the index method could be applied in future, was assembled.  
239 Secondly, both the reference as well as index method pertaining to SARS-CoV-2 diagnosis were  
240 applied to all the study participants and laboratory investigators remained blinded to such  
241 assignments at both the study sites, which independently conducted their investigations.

242  
243 With increasing demand for testing in pandemic situation, several researchers have explored the  
244 possibility of utilizing alternative specimen collection procedures, processing steps and testing  
245 methods. Direct heating of nasopharyngeal swab specimens in universal viral transport (UVT)  
246 medium at 65 °C for 10 minutes without RNA extraction reportedly yielded sensitivity  
247 comparable to the standard method [14]. On the contrary, an earlier evaluation of a direct  
248 extraction method using buffer eluates of the swabs transported in dry tube (without transport  
249 medium) and heat treatment at 98°C for 6 minutes against the reference method on 978 clinical  
250 samples yielded an overall sensitivity of 56 % (95% CI 49.8 % to 61.6 %) and specificity of 95  
251 % (95% CI 93.4 % to 96.8 %) [20]. Pretreatment of such buffer eluates with Proteinase K  
252 followed by heat inactivation was found to improve sensitivity in a pilot laboratory assay of  
253 SARS-CoV-2 [24], consistent with the previous reports from other researchers [13].

254 We conducted the current assessment to evaluate a similar approach of direct extraction from  
255 dry-swabs using TE buffer and proteinase K followed by heat inactivation from naso-pharyngeal  
256 specimens collected from consecutive clinical attendees. This modification over an earlier  
257 version of the test approach [17] increased the overall sensitivity from 56% to 79%.

258 Contrastingly, Srivastan et al [25] reported much higher sensitivity (100%) and specificity  
259 (99.4%) with direct extraction from dry-swabs using low-TE buffer elution, proteinase K pre-  
260 treatment and heat inactivation. Noticeably, the study by Srivastan et al., used archived samples  
261 as well as anterior nasal dry-swabs collected as convenience specimens. Such designs are prone  
262 to introduction of biases that we could avoid by enrolling consecutive clinic attendees from two  
263 different clinic settings.  
264

265 Heat map-based visualization, in the present investigation, demonstrated that the standard RNA  
266 extraction method exhibited enhanced detection of gene targets with lower Ct values (corollary  
267 of higher RNA concentration or viral load in a given condition) compared to the dry swab elution  
268 where RNA-fragmentation during heat inactivation remains a possibility, which could lead to  
269 reduced sensitivity. The difference could further be explained by purification that takes place  
270 during RNA extraction. Moreover, concentration of RNA that is achieved and removal of PCR  
271 inhibitory substances during RNA extraction also could contribute to better yield due to intact  
272 high-quality RNA available for RT-PCR. Noticeably, Chen et al (2020) reported that there was a  
273 50%-66 % drop in RNA copy number after heating at 80°C for 20 minutes [26] while different  
274 inactivation methods were compared. In the present study, the index method failed to detect 17  
275 % and 23% of positive specimens at ICMR-NARI site and STM, Kolkata site respectively.  
276

277 Noticeably, eight positive specimens with low Ct values detected by the reference method were  
278 missed out by the extraction free method at STM, Kolkata. This could be due to the  
279 compromised quality of RNA during extraction process which failed to amplify all three viral  
280 genes. The low detection at STM was not related to site-specific performance issue as the  
281 internal control was detected at low Ct values in these specimens. Rather, different heating  
282 methods used at two study sites could explain the difference in recorded sensitivity due to  
283 resulting difference in time of exposure of samples to 98°C. Hasan et al, (2020) compared  
284 standard method with direct extraction method and showed enhanced detection of human RNase  
285 P compared to viral genes with a difference of 1- 6 Ct values [14]. Burton and colleagues (2021)  
286 therefore recommend local validation of heat-inactivation and examination of its effects on  
287 molecular testing due to considerable variations observed in different studies [27]. These  
288 findings underline the importance of paying attention to the heat treatment method used while  
289 extraction free methods for viral diagnostics would be considered.

290  
291 Importantly, Smyrlaki et al (2020) carried out extensive standardizations of different heat  
292 inactivation protocols. The authors reported that all high temperature ( $\geq 95$  °C) conditions  
293 resulted in similar Ct values and recommended inactivation at 95°C to 98°C [16]. On the other  
294 hand, Mallmann et al (2021) tested different conditions and reported that pretreatment with  
295 Proteinase K and heat treatment at 98°C yielded best results with Ct values similar to that in  
296 standard method.

297  
298 It was observed in the current investigation that the detection of SARS-CoV-2 N gene target was  
299 superior compared to E and RdRP genes. This is in agreement with the previous reports [28],

300 where N-gene based RT-PCR was shown to be more sensitive due to relative abundance of N  
301 gene subgenomic mRNA [29]. The primer–probe set for N1 gene showed better performance due  
302 to shorter amplicon size in another heat inactivation protocol as well [16]. Hence, we maintain  
303 that the primer and probe sets should be carefully chosen if heat inactivation methods are to be  
304 deployed. Our study has further highlighted the importance of deploying appropriate heat  
305 treatment method if RNA-extraction-free detection technique is to be deployed.

306  
307 In conclusion, the evaluated index-method has the potential to serve as an alternative protocol for  
308 identifying SARS-CoV-2 infection in resource limited settings. However, the following  
309 observations appear demanding if using this method in program setting is to be considered; a)  
310 requirement of carefully selected primer and probe sets for better outcome and b) the necessity of  
311 selecting appropriate heat treatment method. The lower sensitivity of this RNA-extraction-free  
312 RT-PCR method in real world setting appears to be one of its limitations.

### 313 **Acknowledgments**

314 We thank Dr. Shailaja Bhavasar, Senior Medical officer, Bhosari Hospital, Dr. Vikalp Bhoi:  
315 Medical Officer, Bhosari Hospital, Ms Asawari Todewale: Laboratory Technician, Project, Mr.  
316 Mahibub Attar: Laboratory Assistant I, ICMR-NARI, Mr. Michael Pereira: Technical Officer-C,  
317 ICMR-NARI, Mr. Atul Sirsat: Technician-2, ICMR-NARI, Mrs. Dipali Kale: Senior Laboratory  
318 Technician-1, ICMR-NARI, Ms. Jyotsna Gokavi: Junior Research Fellowship, ICMR-NARI  
319 and COVID-19 diagnostic team at ICMR-NARI for helping in participant enrollment, sample  
320 collection and sample processing at ICMR-NARI site. We thank Dr Rinku Chakrabarti, Medical  
321

322 Officer and Dr Subhra Chattopadhyay, Senior Resident at STM, Kolkata for helping in  
323 laboratory assays at STM, Kolkata site.

324

### **Financial Support**

325

This work was supported by the Indian Council of Medical Research, Department of Health

326

Research, Ministry of Health and Family Welfare, Government of India. (RFC

327

No.ECD/NTF/47/2020-21, RFC No.ECD/NTF/60/2020-21/Covid)

328

329

### **Conflict of interest**

330

None

331

332

### **Financial Disclosure**

333

The authors do not have any current or former relationships with any organization or entity

334

having a direct financial or personal interest in the subject matter or materials discussed in the

335

article.

336

337

### **Data Availability Statement**

338

The data presented in this study are available on request from the corresponding author. The data

339

are not publicly available due to ethical reasons.

340

341

### **Ethical Statement**

342

The authors assert that all procedures contributing to this work comply with the ethical standards

343

of the national and institutional committees on human experimentation and with the Helsinki

344

345 Declaration of 1975, as revised in 2008. The study was approved by the ICMR Central Ethics  
346 Committee on Human Research (CECHR) (CECHR 018/2020 dated 11<sup>th</sup> August 2020 and 24<sup>th</sup>  
347 October 2020). The study was also approved by the local Institutional Ethics Committees of two  
348 study sites –Ethics Committee, ICMR National AIDS Research Institute (NARI), Pune (Ref  
349 NARI/EC/Approval/20-21/385 dated 14<sup>th</sup> August 2020) and Clinical Research Ethics Committee  
350 (CREC-STM), School of Tropical Medicine, Kolkata (Rf No. CREC-STM/613 dated 10<sup>th</sup>  
351 August 2020).

### 352 **Author Contributions**

353 SP conceived and designed the study, took part in analysis and was the technical advisor and  
354 national coordinator; MJ and SA were the study investigators; MJ and KJS contributed to data  
355 analysis, interpretation of data along with graphical representation; SG, AM, BC, BB, AR MT,  
356 AA, VS, BBa, BG, SD and AC were site investigators and were responsible for clinical,  
357 epidemiologic and laboratory investigations at the respective assessment study sites; RMP  
358 contributed to technical review of the study; BBh participated in discussion around development  
359 of the study protocol and provided critical inputs during implementation of the evaluation work  
360 and in drafting of the reports; MJ, SA, VS, BB and JS wrote the first draft of the manuscript.  
361 Further, SP revised and critically reviewed the manuscript. All authors read and approved the  
362 final version.  
363

364



## 365     **References**

- 366     1. **Andrew Joseph.** (2020). WHO declares coronavirus outbreak a global health emergency;  
367         30 Jan 2020. [https://www.statnews.com/2020/01/30/who-declares-coronavirus-outbreak-](https://www.statnews.com/2020/01/30/who-declares-coronavirus-outbreak-a-global-health-emergency/)  
368         [a-global-health-emergency/](https://www.statnews.com/2020/01/30/who-declares-coronavirus-outbreak-a-global-health-emergency/). Accessed on 10 July 2021.
- 369     2. **WHO** (2020), WHO Director-General's opening remarks at the media briefing on  
370         COVID-19; 11 March 2020.  
371         ([https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-](https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020)  
372         [remarks-at-the-media-briefing-on-covid-19---11-march-2020](https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020)). Accessed on 10 July 2021.
- 373     3. **Vaughan WT.** (1921). *Influenza: An epidemiologic study*. The American Journal of  
374         Hygeine, Monograph series No.1. New Era printing company, Lancaster. Available from:  
375         (<http://hdl.handle.net/2027/nnc2.ark:/13960/t6qz30017>). Accessed on 10 July 2021.
- 376     4. **Panda S, et al.** (2021). Face mask - An essential armour in the fight of India against  
377         COVID-19. *Indian J Med Res*; **153**: 233-237.
- 378     5. **Mina MJ, Andersen KG.** (2021) COVID-19 testing: One size does not fit all. *Science*;  
379         **371**: 126-127.
- 380     6. **Caruana G, et al.** (2020) Diagnostic strategies for SARS-CoV-2 infection and  
381         interpretation of microbiological results. *Clin Microbiol Infect*; **26**: 1178-1182.
- 382     7. **Lu X, et al.** (2020) US CDC Real-Time Reverse Transcription PCR Panel for Detection  
383         of Severe Acute Respiratory Syndrome Coronavirus 2. *Emerg Infect Dis*; **26**: 1654-1665.
- 384     8. **Tang YW, et al.** (2020). Laboratory Diagnosis of COVID-19: Current Issues and  
385         Challenges. *J Clin Microbiol*; **58**: e00512-20.
- 386     9. **Corman VM, et al.** (2020) Detection of 2019 novel coronavirus (2019-nCoV) by real-  
387         time RT-PCR. *Euro Surveill*; **25**: 2000045.

- 388 10. **Nalla AK, et al.** (2020) Comparative Performance of SARS-CoV-2 Detection Assays  
389 Using Seven Different Primer-Probe Sets and One Assay Kit. *J Clin Microbiol*; **58**:  
390 e00557-20.
- 391 11. **Calvez R, et al.** (2020) Molecular detection of SARS-CoV-2 using a reagent-free  
392 approach. *PLoS One*; **15**: e0243266.
- 393 12. **Alcoba-Florez J, et al.** (2020) Fast SARS-CoV-2 detection by RT-qPCR in preheated  
394 nasopharyngeal swab samples. *Int J Infect Dis*; **97**: 66-68.
- 395 13. **Chu AW, et al.** (2020) Evaluation of simple nucleic acid extraction methods for the  
396 detection of SARS-CoV-2 in nasopharyngeal and saliva specimens during global shortage  
397 of extraction kits. *J Clin Virol* ; **129**: 104519.
- 398 14. **Hasan MR, et al.** (2020) Detection of SARS-CoV-2 RNA by direct RT-qPCR on  
399 nasopharyngeal specimens without extraction of viral RNA. *PLoS One*; **15**: e0236564.
- 400 15. **Fomsgaard AS, Rosenstjerne MW.** (2020) An alternative workflow for molecular  
401 detection of SARS-CoV-2 - escape from the NA extraction kit-shortage, Copenhagen,  
402 Denmark, March 2020. *Euro Surveill* ; **25**: 2000398.
- 403 16. **Smyrlaki I, et al.** (2020) Massive and rapid COVID-19 testing is feasible by extraction-  
404 free SARS-CoV-2 RT-PCR. *Nat Commun* ; **11**: 4812.
- 405 17. **Kiran U, et al.** (2020) Easing diagnosis and pushing the detection limits of SARS-CoV-  
406 2. *Biol Methods Protoc* ; **5**: bpa017.
- 407 18. **de Paula VS, Villar LM, Coimbra Gaspar AM.** (2003) Comparison of four extraction  
408 methods to detect hepatitis A virus RNA in serum and stool samples. *Braz J Infect Dis* ; **7**:  
409 135-141.

- 410 19. Specimen collection, transport and packaging guidelines for 2019 novel Coronavirus  
411 (2019-nCoV).  
412 [https://www.mohfw.gov.in/pdf/5Sample%20collection\\_packaging%20%202019-](https://www.mohfw.gov.in/pdf/5Sample%20collection_packaging%20%202019-)  
413 [nCoV.pdf](https://www.mohfw.gov.in/pdf/5Sample%20collection_packaging%20%202019-nCoV.pdf)
- 414 20. Indian Council of Medical Research (ICMR). Validation of a dry swab based sample  
415 collection and RNA-extraction-free diagnostic method for SARS-CoV-2: A multicentric  
416 study. ICMR Report, September 2020.
- 417 21. **Flahault A, Cadilhac M, Thomas G.** (2005) Sample size calculation should be  
418 performed for design accuracy in diagnostic test studies. *J Clin Epidemiol* ; **58**: 859-862.
- 419 22. **Rishu AH, et al.** (2017) Time required to initiate outbreak and pandemic observational  
420 research. *J Crit Care* ; **40**: 7-10.
- 421 23. **Ueda M, et al.** (2021) Japan's Drug Regulation During the COVID-19 Pandemic:  
422 Lessons From a Case Study of Favipiravir. *Clin Pharmacol Ther*, doi: 10.1002/cpt.2251.
- 423 24. **Mallmann L, et al.** (2021) Proteinase K treatment in absence of RNA isolation classical  
424 procedures is a quick and cheaper alternative for SARS-CoV-2 molecular detection. *J*  
425 *Virol Methods* : **293**:114131.
- 426 25. **Srivatsan S, et al.** (2020) SwabExpress: An end-to-end protocol for extraction-free  
427 COVID-19 testing. *bioRxiv*: the preprint server for biology, 2020.04.22.056283.  
428 <https://doi.org/10.1101/2020.04.22.056283>.
- 429 26. **Chen H, et al.** (2020) Influence of Different Inactivation Methods on Severe Acute  
430 Respiratory Syndrome Coronavirus 2 RNA Copy Number. *J Clin Microbiol* ; **58**:  
431 e00958-20.

- 432 27. **Burton J, et al.** (2021) The effect of heat-treatment on SARS-CoV-2 viability and  
433 detection. *J Virol Methods* ; **290**:114087.
- 434 28. **Chu DKW, et al.** (2020) Molecular diagnosis of a novel coronavirus (2019-nCoV)  
435 causing an outbreak of pneumonia. *Clin Chem* ; **66**: 549–555.
- 436 29. **Moreno JL, et al.** (2008) Identification of a coronavirus transcription enhancer. *J Virol* ;  
437 **82**: 3882–3893.
- 438  
439  
440  
441

442  
443  
444  
445  
446

**Table 1** Primer Probe sets of RT-PCR Kit used for assay

<b>S No</b>	<b>Target</b>	<b>Reporter</b>	<b>Primer Sequence</b>	<b>Amplicon Size</b> <sup>447</sup>
1.	E gene	FAM	<b>F:</b> ACAGGTACGTTAATAGTTAATAGCGT <b>R:</b> ATATTGCAGCAGTACGCACACA	113 bp <sup>448</sup> 449
2.	RdRp gene	CY5	<b>F:</b> GTGAAATGGTCATGTGTGGCGG <b>R:</b> CAAATGTTAAAAACACTATTAGCATA	100 bp 450 451
3.	N gene	HEX	<b>F:</b> TTCCTATGGTGCTAACAAAGACG <b>R:</b> CTTGAGGAAGTTGTAGCACGATTG	129 bp 452 453
4.	Human Rnase P	TEXAS RED	<b>F:</b> AGATTTGGACCTGCGAGCG <b>R:</b> GAGCGGCTGTCTCCACAAGT	65 bp

454 **Table 2** Demographic profile of study participants

455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491

<b>Characteristics</b>	<b>Frequency (%)</b>
Total number of participants	1138
<b>Male (n=767)</b>	
Mean age $\pm$ SD (year)	38.47 $\pm$ 13.2
Median age (year) [IQR]	37 [27-49]
<b>Female (n=371)</b>	
Mean age $\pm$ SD (year)	35.97 $\pm$ 13.7
Median age (year) [IQR]	34 [24-45]
<b>Age group (year)</b>	<b>Total n (%)</b>
18-30	437 (38)
31- 40	247 (22)
41-50	235 (21)
51-60	160 (14)
>60	59 (5)
Total	1138 (100)
<b>Symptoms (n=342)</b>	
Cough	120 (35.1)
Fever	178 (52.0)
Bodyache	40 (11.7)
Breathlessness	12 (3.5)
Sore throat	24 (7.0)
Nausea	4 (1.2)
Heamoptysis	1 (0.3)
Vomiting	1 (0.3)
Chest pain	2 (0.6)
Anosmia	12 (3.5)
Others	79 (23.1)

**Table 3** Performance of the RNA Extraction Free Index Method in Current Investigation

492  
493  
494  
495

	Study site		
	NARI, Pune	STM, Kolkata	Overall
Sensitivity (%) (95 % CI)	82 (70 to 91)	76.4 (65 to 86)	78.90 (71 to 86)
Specificity (%) (95 % CI)	98.3 (97 to 99)	100 (99 to 100)	99 (98 to 99.6)
Positive predictive value (%) (95 % CI)	83.6 (71 to 92)	100 (94 to 100)	92 (85 to 96)
Negative predictive value (%) (95 % CI)	98 (97 to 99)	96.6 (95 to 98)	97 (96 to 98)

496  
497

## Figure Legends

498

**Figure 1** Schematic illustration of modified dry tube-based heat inactivation method followed by

499

RT-PCR for detection of SARS-CoV-2. 1. Addition of TE-Proteinase K buffer to the tube

500

containing swabs 2. Incubation of swabs in buffer to extract viral particles 3. Transfer of viral

501

extract 4. Inactivation of the virus by heating. 5. Setting up RT-PCR reaction and interpretation

502

of assay. NP= Nasopharyngeal swab, OP= Oropharyngeal swab.

503

**Figure 2** Heat map of cycle threshold (Ct) values for E, RdRP and N genes detected by reference

504

and index methods on clinical samples from ICMR-NARI (n=54) and STM, Kolkata (n=71). The

506

heat map is ranked by N gene Ct. Ct values of human Rnase P used as control in RT PCR is

507

shown in the right. A Ct value  $\leq 40$  is considered as positive. Samples that are positive for all

508

three viral genes are indicated as strong positives by an arrow on the left.

509

**Figure 3** Flowchart showing enrolment of participants at two study sites (ICMR-NARI, Pune,

510

Maharashtra and STM, Kolkata, West Bengal).

512

**Figure 4** Scatter plot of Ct values for matched samples tested by reference and index method for

513

a) E gene b) RdRP gene and c) N gene

515

\* Of 103 samples having E gene detection through VTM, 81 were detected through index

516

method

517

† Of 106 samples having RdRP gene detection through VTM, 80 were detected through index

518

method

519

‡ Of 124 samples having N gene detection through VTM, 98 were detected through index

520

method

521

522



100% 100%  
100% 100% 100% 100%

100% 100%  
100% 100% 100% 100%

100% 100% 100% 100%  
100% 100% 100% 100%



100% 100% 100% 100%  
100% 100% 100% 100%


100% 100% 100% 100%  
100% 100% 100% 100%

100% 100% 100% 100%  
100% 100% 100% 100%




**a) ICMR-NARI, Pune**


Swab in VTM (Reference method, n=54)



Swab in dry tube (Index method, n=54)

**b) STM, Kolkata**

Swab in VTM (Reference method, n=71)



Swab in Dry tube (Index method, n=71)

